# EDGAR Filing Document

**Accession Number:** 0001589150
**File Stem:** 0001641172-25-026585
**Filing Date:** 2025-9
**Character Count:** 2322
**Document Hash:** f4f9b0d63808110c6669724a7002469e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-026585.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001641172-25-026585

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250904

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Regen BioPharma Inc
- **CENTRAL INDEX KEY:** 0001589150
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 455192997
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4700 SPRING ST #304
- **CITY:** LA MESA
- **STATE:** CA
- **ZIP:** 91942
- **BUSINESS PHONE:** 619-722-5505

**MAIL ADDRESS:**
- **STREET 1:** 4700 SPRING ST #304
- **CITY:** LA MESA
- **STATE:** CA
- **ZIP:** 91942

<u>Via Edgar</u>

Securities and Exchange Commission

100 F. Street, NE

Washington, D.C. 20549-7410

**Attn:** Tyler Howes

September 4, 2025

---

| | |
|:---|:---|
| **Re:** | Regen BioPharma, Inc.<br> Offering Statement on Form 1-A Filed August 29, 2025<br> File No.: 024-12654 |

---

Dear Mr. Howes

Regen Biopharma, Inc. (the "Company") hereby requests qualification of the above-referenced offering statement at 9:30 a.m., Eastern Time, on September 5, 2025 or as soon thereafter as is practicable.

In connection with the foregoing request, the Company hereby confirms and acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. should
 the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from
 taking any action with respect to the filing;

2. the
 action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company
 from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

3. the
 Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person
 under the federal securities laws of the United States.

If you should require any additional information or clarification, please do not hesitate to contact me.

---

| |
|:---|
| Very truly yours, |
| */s/ David R.Koos* |
| David R. Koos, |
| Chairman & CEO |

---